<DOC>
	<DOCNO>NCT01641575</DOCNO>
	<brief_summary>The purpose first part study evaluate safety , tolerability , pharmacokinetics ascend dos gemcitabine elaidate combination cisplatin give patient advance solid tumor , select dose evaluation second part study . The purpose second part study determine safety , tolerability , exploratory clinical activity gemcitabine elaidate combination cisplatin give patient Stage IIIb/IV non-small-cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>A Dose Ascending Study Gemcitabine Elaidate ( CO-101 ) Combination With Cisplatin</brief_title>
	<detailed_description>The chemotherapy doublet cisplatin gemcitabine effective regimen solid tumor include NSCLC . Entry gemcitabine tumor cell show dependent specific membrane transporter protein , particularly human equilibrative nucleoside transporter 1 ( hENT1 ) . Patients low tumor hENT-1 expression may respond poorly gemcitabine-containing chemotherapy . Gemcitabine elaidate ( CO-1.01 ) fatty acid derivative gemcitabine , enter cell absence hENT1 . CO-1.01 therefore , may overcome hENT1-mediated resistance gemcitabine . CO-1.01 currently evaluate single agent pivotal randomize trial 360 patient metastatic pancreatic adenocarcinoma . The appropriate dose CO-1.01 give part combination therapy platinum agent cisplatin yet know . The objective study : - determine maximum tolerate dose ( MTD ) CO-1.01 combine fix dose cisplatin patient solid tumor - select recommend dose ( RD ) dose expansion patient Stage IIIb/IV NSCLC - explore clinical activity CO-1.01 patient Stage IIIb/IV NSCLC</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Understand sign institutional review board/independent ethic committeeapproved informed consent form ( ICF ) prior studyspecific evaluation Life expectancy least 3 month ECOG performance status 0 1 ≥ 18 year time ICF sign Adequate hematological biological function Histologically cytologically confirm solid tumor malignancy ( Part 1 ) Histologically cytologically confirm stage IIIb/IV NSCLC ( Part 2 ) Symptomatic central nervous system metastases Concomitant treatment prohibit medication , e.g . chemotherapy , radiation , hormonal treatment ( except corticosteroid ) , immunotherapy ≤ 14 day prior CO1.01 treatment Treatment previous regimen CO1.01 Participation another therapeutic clinical study within 14 day enrollment clinical study Surgical procedure ≤ 14 day prior CO1.01 administration History allergy gemcitabine , gemcitabine elaidate egg Known allergic/hypersensitivity reaction cisplatin , platinum agent , platinum contain compound Peripheral neuropathy ≥ Grade 1 Females pregnant breastfeeding Refusal use adequate contraception fertile patient Presence serious unstable concomitant systemic disorder incompatible clinical study Any reason investigator considers patient participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>CO-1.01</keyword>
	<keyword>CO-101</keyword>
	<keyword>gemcitabine elaidate</keyword>
	<keyword>hENT1</keyword>
	<keyword>nucleoside equilibrative transporter</keyword>
	<keyword>solid tumor</keyword>
	<keyword>non-small-cell lung cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>lung cancer</keyword>
</DOC>